
Opinion|Videos|September 12, 2024
Overview of Advanced Therapies in cGVHD
Medical experts discuss advanced therapies in cGVHD.
Advertisement
Video content above is prompted by the following:
- Dr Holtan:Both ruxolitinib and ibrutinib are approved for use in cases of cGVHD that have failed 1 or more lines of systemic therapy.
Briefly summarize and critique clinical trial data with ruxolitinib (REACH3) and ibrutinib (Miklos D, et al. Blood. 2017) in patients with cGVHD.
Comment on adverse effects most frequently seen with ruxolitinib and ibrutinib and how you manage them.
In which patients would you hesitate to use ruxolitinib or ibrutinib (eg, patients at risk of developing thrombocytopenia, etc)?
- Belumosudil is approved for treatment of cGVHD after failure of 2 or more systemic therapies. Can you elaborate on anti-inflammatory and antifibrotic properties of belumosudil and results from preclinical and human studies in reduction of fibrosis (Flynn R, et al. Blood. 2016)?
- How do these properties distinguish belumosudil from other targeted therapies for cGVHD?
Advertisement
Related to this article

Jorge Cortes, MD, discusses response-based ponatinib dosing, mutation testing, and managing cardiovascular risk in resistant CML.

The EC approved every-6-week maintenance dosing and shorter 350-mg infusions for cemiplimab across all 6 EU indications.

Faculty convened at an OncLive Scientific Interchange and Workshop to guide oncology fellows through designing a cancer clinical trial development program, from concept to approval.

The FDA granted priority review to sonesitatug vedotin for previously treated CLDN18.2-positive advanced gastroesophageal cancers.

UCLA Health performs its first single-port robotic lobectomy, using a new technique that could reduce pain and make recovery easier for patients with lung cancer.

Narek Shaverdian, MD, outlines how novel strategies may reshape unresectable stage III NSCLC management.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Priority Review to Sonesitatug Vedotin in CLDN18.2+ Gastroesophageal Cancer
2
EC Approves Extended Cemiplimab Dosing in Skin, Lung, and Cervical Cancers
3
Dose Optimization, Evidentiary Bars, and Patient Selection Shape Trial Design in EGFR- and HER2-Mutant NSCLC
4
Defining High-Risk Localized Prostate Cancer and the DASL-HiCaP Trial
5


